Scarica l'app Stockscreener
41.99
0.11%
0.045
Dopo l'orario di chiusura:
38.27
-3.725
-8.87%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$41.95
Aprire:
$42.87
Volume 24 ore:
9.64M
Relative Volume:
0.84
Capitalizzazione di mercato:
$16.41B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-4.8104
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-0.49%
1M Prestazione:
+22.43%
6M Prestazione:
+60.78%
1 anno Prestazione:
+31.77%
Intervallo 1D:
$41.68
$45.50
Intervallo di 1 settimana:
$39.50
$45.50
Portata 52W:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
41.99 | 16.39B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
F.D.A. Refuses to Review Moderna Flu Vaccine - The New York Times
Moderna says US refusing to review mRNA-based flu shot | National | dailygazette.com - The Daily Gazette
Moderna Says US Refusing To Review MRNA-based Flu Shot - Barron's
FDA refuses to review Moderna’s flu vaccine in latest setback - GMToday.com
Moderna Cites Changing Advice As US FDA Refuses To File Flu Vaccine BLA - Citeline News & Insights
Why Did Moderna Stock Tumble Nearly 10% After Hours Today? - Stocktwits
FDA Refuses To Review Moderna's Flu Vaccine Application - Health and Me
FDA Tosses Flu Vaccine Application Back To Moderna With RTF Letter - Citeline News & Insights
FDA Refuses to Consider Approving Use of Moderna’s New Flu Vaccine - The Wall Street Journal
Moderna (MRNA) Faces FDA Setback with Influenza Vaccine Applicat - GuruFocus
Moderna (MRNA) Shares Decline After FDA Rejects Flu Vaccine Appl - GuruFocus
FDA refuses to review Moderna's flu vaccine application - The Business Journals
Moderna shares slide 7% after FDA refuses to review flu vaccine - Investing.com UK
FDA Refuses to Review Moderna’s Flu Vaccine in Latest Setback - Bloomberg.com
Moderna says FDA refuses its application for new mRNA flu vaccine - WRAL
FDA refuses to review Moderna’s influenza vaccine application By Investing.com - Investing.com India
Moderna says US FDA refuses to review its influenza vaccine - TradingView
FDA refuses to review Moderna's influenza vaccine application - Reuters
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 - ACCESS Newswire
FDA refuses to review Moderna’s application for mRNA flu vaccine, company says - AOL.com
Fda refuses to consider approving use of Moderna's new flu vaccineWSJ - marketscreener.com
Moderna says FDA refuses to review its application for experimental flu shot - CNBC
FDA declines to review Moderna's mRNA flu shot - NBC News
Moderna signs 5-year vaccine deal with Mexican government - NBC Boston
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico - USA Today
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell - The Motley Fool
Moderna inks five-year Mexico deal as it pushes geographic expansion to hit breakeven - The Business Journals
Moderna to supply respiratory vaccines to Mexico (MRNA:NASDAQ) - Seeking Alpha
Moderna, Mexico Partner To Boost Local Vaccine Production - Benzinga
Jim Cramer on Moderna: "One of the Hottest Stocks in the Market This Year" - Finviz
Jim Cramer on Moderna: “One of the Hottest Stocks in the Market This Year” - Yahoo Finance Singapore
Moderna signs mRNA vaccine supply and tech transfer deal with Mexico By Investing.com - Investing.com South Africa
Moderna Signs Long-Term mRNA Manufacturing Agreement With Mexican Government - marketscreener.com
United States Biotechnology Market to hit US$ 1.5 Trillion - openPR.com
Moderna signs mRNA vaccine supply and tech transfer deal with Mexico - Investing.com India
What Does the Street Think About Moderna, Inc. (MRNA)? - Insider Monkey
Moderna (MRNA) Gets a Sell from Bank of America Securities - The Globe and Mail
Should You Buy Moderna Before Feb. 13? - The Globe and Mail
Moderna (MRNA) Laps the Stock Market: Here's Why - Yahoo Finance Australia
How Investors Are Reacting To Moderna (MRNA) Denied Immunity In High-Stakes Vaccine Patent Case - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? - TradingView
Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? - Nasdaq
A Double Blow for Moderna – Seqirus Topples Two mRNA Patent Applications - Pearce IP
1 Stock to Buy, 1 Stock to Sell This Week: Cisco, Moderna - Investing.com Nigeria
Moderna Balances $5b Patent Trial Risk With Oncology Leadership Shift - Yahoo Finance
United StatesGoodwin Advises Moderna On Strategic Collaboration With Recordati To Globally Commercialize Investigational Propionic Acidemia Therapeutic (MRNA-3927) For $50 Million Upfront And Up To $110 Million In - Mondaq
Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline - GuruFocus
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Moderna faces $5 billion mRNA patent lawsuit after ‘Star Trek’ ruling - thestreet.com
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock - Yahoo Finance
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):